



The Underrecognized Burden of Hypogonadism in Physical Medicine and Rehabilitation: Implications for Anabolic Therapeutics

Lucas Caseri Câmara^{a*}

^a *Department of Specialization in Clinical Anabolism, College of Governance, Engineering and Education of São Paulo - FGE-SP, Brazil.*

Author's contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

Article Information

DOI: <https://doi.org/10.9734/ajrimps/2024/v13i4287>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/129047>

Letter to the Editor

Received: 25/10/2024
Accepted: 27/12/2024
Published: 28/12/2024

Dear Editor,

Testosterone deficiency (hypogonadism) can be highly prevalent among patients frequently encountered within the scope of care in Physical Medicine and Rehabilitation (PM&R) [1,2]. This condition negatively affects anabolic capacity, leading to decreased muscle mass, strength, and functional outcomes. Given its significant prevalence across diverse clinical populations, routine screening for hypogonadism and

exploration of anabolic therapies must be prioritized to optimize rehabilitation outcomes [1,2].

Low testosterone levels contribute to sarcopenia, reduced strength, impaired recovery, and increased disability. Testosterone exerts anabolic effects by promoting protein synthesis, enhancing lean body mass, and improving muscle performance—functions essential for rehabilitation success [3]. In patients

*Corresponding author: E-mail: lucascc_med@hotmail.com;

with chronic conditions such as stroke [4], spinal cord injury (SCI) [5], traumatic brain injury (TBI) [6], chronic pain [7], and multiple sclerosis [8], hypogonadism is particularly common.

1. PREVALENCE ACROSS PM&R POPULATIONS

In stroke survivors, hypogonadism has been reported in up to 66.3% of male ischemic stroke patients, with higher rates in those with type 2 diabetes mellitus [4]. Similarly, hypogonadism affects between 35% and 65% of men with chronic SCI, significantly higher than the general population [5]. In multiple sclerosis, nearly 39% of men demonstrate testosterone deficiency, which correlates with worse clinical outcomes and disability [8].

Among patients with TBI, the prevalence ranges from 15% to 68% due to pituitary axis dysfunction [6]. Hypogonadism is also notably prevalent in chronic pain patients on long-term opioid therapy, affecting up to 63%, with rates increasing with higher opioid doses [7]. These findings reflect a systemic issue that exacerbates functional impairment, muscle loss, and poor rehabilitation outcomes.

2. CLINICAL CONSEQUENCES OF HYPOGONADISM

Testosterone deficiency has profound implications for rehabilitation. It accelerates muscle atrophy, reduces strength, and diminishes physical performance. In older men with mobility limitations and low testosterone, a recent systematic review has shown that testosterone replacement significantly may improve lean body mass, grip strength, and self-reported physical function [9]. Furthermore, testosterone therapy in ill older men demonstrated improved Functional Independence Measure (FIM) scores and grip strength compared to placebo, highlighting its role in enhancing rehabilitation outcomes [1-3].

Low testosterone is also associated with higher mortality rates. A meta-analysis involving over 16,000 men revealed a 35% increased risk of mortality among those with low testosterone levels [10]. This underscores the importance of addressing hypogonadism as part of comprehensive rehabilitation care.

3. POTENTIAL ROLE OF ANABOLIC THERAPIES

The use of anabolic-androgenic steroids (AAS), including testosterone derivatives, has shown promise in reversing catabolic states and improving clinical outcomes in chronic diseases [1-3,9]. Testosterone supplementation increases muscle protein synthesis, improves physical function, and enhances quality of life [1-3,9]. In critically ill patients, anabolic steroids have been proposed to counteract catabolism, improving muscle mass and recovery [3]. Evidence also suggests that AAS therapy in chronic illnesses, such as burns and renal disease, leads to significant improvements in lean body mass and physical function [1-3,9].

4. CALL FOR ACTION

Despite the growing body of evidence, routine screening for hypogonadism in PM&R remains underutilized. This represents a missed opportunity to identify and address a modifiable factor contributing to poor functional outcomes [1-3,9]. Given the high prevalence of testosterone deficiency and its significant impact on muscle preservation, strength, and recovery, systematic evaluation of testosterone levels should be integrated into PM&R practice. Furthermore, testosterone replacement therapy should be considered as a potential adjunct to rehabilitation in hypogonadal patients, with careful monitoring of benefits and risks.

Future research should focus on large-scale trials to confirm the efficacy and safety of anabolic therapies in PM&R populations. Robust data on the impact of testosterone replacement on long-term functional outcomes, independence, and quality of life are essential to guide clinical practice.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

The authors declare that generative AI was used only at the final stage of manuscript preparation (after writing) and exclusively for linguistic refinement in English Language (Name: ChatGPT; Version: GPT-4; Model: OpenAI's Large Language Model; Source: OpenAI - <https://openai.com>). No original text was generated or substantively edited by the AI.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. *J Clin Endocrinol Metab.* 2001 Nov;86(11):5108-17. DOI: 10.1210/jcem.86.11.7983. PMID: 11701661.
2. Woerdeman J, de Ronde W. Therapeutic effects of anabolic androgenic steroids on chronic diseases associated with muscle wasting. *Expert Opin Investig Drugs.* 2011 Jan;20(1):87-97. DOI: 10.1517/13543784.2011.544651. PMID: 21158691.
3. Spratt DI. Altered gonadal steroidogenesis in critical illness: Is treatment with anabolic steroids indicated? *Best Pract Res Clin Endocrinol Metab.* 2001 Dec;15(4):479-94. DOI: 10.1053/beem.2001.0165. PMID: 11800519.
4. Morgunov LY, Denisova IA, Rozhkova TI, Stakhovskaya LV, Skvortsova VI. Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. *Aging Male.* 2020 Mar;23(1):71-80. DOI: 10.1080/13685538.2018.1487932. Epub 2018 Jul 31. PMID: 30064273.
5. Sullivan SD, Nash MS, Tefera E, Tinsley E, Blackman MR, Groah S. Prevalence and etiology of hypogonadism in young men with chronic spinal cord injury: A Cross-Sectional Analysis from Two University-Based Rehabilitation Centers. *PM R.* 2017 Aug;9(8):751-760. DOI: 10.1016/j.pmrj.2016.11.005. Epub 2016 Nov 18. PMID: 27871967; PMCID: PMC5436946.
6. Hohl A, Mazzuco TL, Coral MH, Schwarzbald M, Walz R. Hypogonadism after traumatic brain injury. *Arq Bras Endocrinol Metabol.* 2009 Nov;53(8):908-14. DOI: 10.1590/s0004-27302009000800003. PMID: 20126842.
7. de Vries F, Bruin M, Lobatto DJ, Dekkers OM, Schoones JW, van Furth WR, et al. Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. *J Clin Endocrinol Metab.* 2020 Mar 1;105(3):1020-9. DOI: 10.1210/clinem/dgz022. PMID: 31511863; PMCID: PMC7054712.
8. Bove R, Musallam A, Healy BC, Raghavan K, Glanz BI, Bakshi R, et al. Low testosterone is associated with disability in men with multiple sclerosis. *Mult Scler.* 2014 Oct;20(12):1584-92. DOI: 10.1177/1352458514527864. Epub 2014 Apr 7. PMID: 24710799; PMCID: PMC4188801.
9. Falqueto H, Júnior JLR, Silvério MNO, Farias JCH, Schoenfeld BJ, Manfredi LH. Can conditions of skeletal muscle loss be improved by combining exercise with anabolic-androgenic steroids? A systematic review and meta-analysis of testosterone-based interventions. *Rev Endocr Metab Disord.* 2021 Jun;22(2):161-178. DOI: 10.1007/s11154-021-09634-4. Epub 2021 Mar 30. PMID: 33783694.
10. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: A systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2011 Oct;96(10):3007-19. DOI: 10.1210/jc.2011-1137. Epub 2011 Aug 3. PMID: 21816776

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/129047>